Clinical Trial Update: Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating ribociclib plus letrozole in relapsed estrogen receptor-positive cancers of female reproductive tract (ovarian, fallopian tube, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Letrozole (letrozole)
• Ribociclib (ribociclib)

Snippet

Sponsor: Mayo Clinic | Conditions: Estrogen Receptor Positive, Postmenopausal | Phase 2 | Status: COMPLETED | Results posted: 2019-10-18